The Susceptibility of MDR-K. Pneumoniae to Polymyxin B Plus its Nebulised Form Versus Polymyxin B Alone in Critically Ill South Asian Patients

1Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. Crit Care Med. 199;27(5):887-892. Richards MJ Edwards JR Culver DH Gaynes RP Nosocomial infections in medical intensive care units in the United States Crit Care Med 199275887–89210.1097/00003246-199905000-00020Search in Google Scholar

2Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995. Am J Respir Crit Care Med. 1996;153(5):1711-1725. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement American Thoracic Society, November 1995. Am J Respir Crit Care Med 1996 15351711 172510.1164/ajrccm.153.5.8630626Search in Google Scholar

3Porzecanski I, Bowton DL. Diagnosis and treatment of ventilator-associated pneumonia. Chest. 2006;130(2):597-604. Porzecanski I Bowton DL Diagnosis and treatment of ventilator-associated pneumonia Chest 20061302597 60410.1378/chest.130.2.597Search in Google Scholar

4Wang Y, Eldridge N, Metersky ML, et al. National trends in patient safety for four common conditions, 2005-2011. N Engl J Med. 2014;370(4):341-351. Wang Y Eldridge N Metersky ML et al National trends in patient safety for four common conditions, 2005-2011 N Engl J Med 20143704341 35110.1056/NEJMsa1300991Search in Google Scholar

5American Thoracic Society, Infectious Diseases Society of America: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med.2005;171(4):388-416. American Thoracic Society, Infectious Diseases Society of America: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia Am J Respir Crit Care Med 2005 1714388 41610.1164/rccm.200405-644STSearch in Google Scholar

6Melsen WG, Rovers MM, Koeman M, Bonten MJ. Estimating the attributable mortality of ventilator-associated pneumonia from randomised prevention studies. Crit Care Med.2011;39(12):2736-2742. Melsen WG Rovers MM Koeman M Bonten MJ Estimating the attributable mortality of ventilator-associated pneumonia from randomised prevention studies Crit Care Med 2011 39122736 274210.1097/CCM.0b013e3182281f33Search in Google Scholar

7Melsen WG, Rovers MM, Groenwold RH, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis2013;13(8):665-671. Melsen WG Rovers MM Groenwold RH et al Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies Lancet Infect Dis 2013 138665 67110.1016/S1473-3099(13)70081-1Search in Google Scholar

8Ruiz J, Gordon M, Villarreal E, Frasquet J, Sánchez MÁ, Martín M, Castellanos Á, Ramirez P. Influence of antibiotic pressure on multi-drug resistant Klebsiella pneumoniae colonisation in critically ill patients. Antimicrob Resist Infect Control 2019;8:38. Ruiz J Gordon M Villarreal E Frasquet J Sánchez MÁ Martín M Castellanos Á Ramirez P Influence of antibiotic pressure on multi-drug resistant Klebsiella pneumoniae colonisation in critically ill patients Antimicrob Resist Infect Control 201983810.1186/s13756-019-0484-8637512130809381Search in Google Scholar

9US Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Available at: http://www.cdc.gov/drugresistance/threat-report-2013/ index.html (accessed 18 January 2020). US Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States 2013 Available at http://www.cdc.gov/drugresistance/threat-report-2013/ index.html (accessed 18 January 2020)Search in Google Scholar

10Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspect Medicin Chem. 2014;6:25-64. Fair RJ Tor Y Antibiotics and bacterial resistance in the 21st century Perspect Medicin Chem 2014625 6410.4137/PMC.S14459415937325232278Search in Google Scholar

11Dsouza R, Pinto NA, Hwang I, et al. Panel strain of Klebsiella pneumoniae for beta-lactam antibiotic evaluation: their phenotypic and genotypic characterisation. PeerJ.2017;5:e2896. Dsouza R Pinto NA Hwang I et al Panel strain of Klebsiella pneumoniae for beta-lactam antibiotic evaluation: their phenotypic and genotypic characterisation PeerJ 2017 5e289610.7717/peerj.2896525193228133574Search in Google Scholar

12Yan Q, Zhou M, Zou M, Liu WE. Hypervirulent Klebsiella pneumoniae induced ventilator-associated pneumonia in mechanically ventilated patients in China. Eur J Clin Microbiol Infect Dis. 2016;35(3):387-396. Yan Q Zhou M Zou M Liu WE Hypervirulent Klebsiella pneumoniae induced ventilator-associated pneumonia in mechanically ventilated patients in China Eur J Clin Microbiol Infect Dis 2016353387 39610.1007/s10096-015-2551-2Search in Google Scholar

13World Health Organization. WHO Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. Available at: https://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/ (accessed 20 January 2020). World Health Organization. WHO Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics Available at https://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/ (accessed 20 January 2020Search in Google Scholar

14Bassetti M, Righi E, Carnelutti A, et al. Multidrug-resistant Klebsiella pneumoniae: challenges for treatment, prevention and infection control. Expert Rev Anti Infect Ther. 2018;16(10):749-761. Bassetti M Righi E Carnelutti A et al Multidrug-resistant Klebsiella pneumoniae: challenges for treatment, prevention and infection control Expert Rev Anti Infect Ther 20181610749 76110.1080/14787210.2018.1522249Search in Google Scholar

15Hsia Y, Lee BR, Versporten A, et al. Use of the WHO Access, Watch, and Reserve classification to define patterns of hospital antibiotic use (AWaRe): an analysis of paediatric survey data from 56 countries. Lancet Glob Health. 2019;7(7):e861-e871. Hsia Y Lee BR Versporten A et al Use of the WHO Access, Watch, and Reserve classification to define patterns of hospital antibiotic use (AWaRe): an analysis of paediatric survey data from 56 countries Lancet Glob Health 201977e861 e87110.1016/S2214-109X(19)30071-3Search in Google Scholar

16Aslam B, Wang W, Arshad MI, et al. Antibiotic resistance: a rundown of a global crisis. Infect Drug Resist. 2018;11:1645-1658. Aslam B Wang W Arshad MI et al Antibiotic resistance: a rundown of a global crisis Infect Drug Resist 2018111645 165810.2147/IDR.S173867618811930349322Search in Google Scholar

17Storm DR, Rosenthal KS, Swanson PE. Polymyxin and related peptide antibiotics. Annu Rev Biochem. 1977;46:723-763. Storm DR Rosenthal KS Swanson PE Polymyxin and related peptide antibiotics Annu Rev Biochem 197746723 76310.1146/annurev.bi.46.070177.003451197881Search in Google Scholar

18Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10-39. Tsuji BT Pogue JM Zavascki AP et al International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP) Pharmacotherapy 201939110 3910.1002/phar.2209743725930710469Search in Google Scholar

19Poirel L, Jayol A, Nordmann P. Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin Microbiol Rev. 2017;30(2):557-596. Poirel L Jayol A Nordmann P Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes Clin Microbiol Rev 2017302557 59610.1128/CMR.00064-16535564128275006Search in Google Scholar

20Lin YW, Zhou Q, Onufrak NJ, et al. Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model. Antimicrob Agents Chemother. 2017;61(8):e00211-17. Lin YW Zhou Q Onufrak NJ et al Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model Antimicrob Agents Chemother 2017618e00211 1710.1128/AAC.00211-17552763028559256Search in Google Scholar

21Standards of clinical and laboratory standards institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute. 2020. Available at: https:// clsi.org/media/3481/m100ed30_sample.pdf (accessed 2 February 2020). Standards of clinical and laboratory standards institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. CLSI supplement M100 Wayne, PA Clinical and Laboratory Standards Institute 2020 Available at https://clsi.org/media/3481/m100ed30_sample.pdf (accessed 2 February 2020)Search in Google Scholar

22Tuon FF, Graf ME, Merlini A, et al. Risk factors for mortality in patients with ventilator-associated pneumonia caused by carbapenem-resistant Enterobacteriaceae. Braz J Infect Dis. 2017;21(1):1-6. Tuon FF Graf ME Merlini A et al Risk factors for mortality in patients with ventilator-associated pneumonia caused by carbapenem-resistant Enterobacteriaceae Braz J Infect Dis 20172111 610.1016/j.bjid.2016.09.00827821248Search in Google Scholar

23Moreira FT, Serpa Neto A. Sedation in mechanically ventilated patients-time to stay awake? Ann Transl Med. 2016;4(19):382. Moreira FT Serpa Neto A Sedation in mechanically ventilated patients-time to stay awake? Ann Transl Med 201641938210.21037/atm.2016.09.37507585327826584Search in Google Scholar

24Maxson T, Mitchell DA. Targeted Treatment for Bacterial Infections: Prospects for Pathogen-Specific Antibiotics Coupled with Rapid Diagnostics. Tetrahedron. 2016;72(25):3609-3624. Maxson T Mitchell DA Targeted Treatment for Bacterial Infections: Prospects for Pathogen-Specific Antibiotics Coupled with Rapid Diagnostics Tetrahedron 201672253609 362410.1016/j.tet.2015.09.069494182427429480Search in Google Scholar

25Hasan MJ, Rabbani R, Bachar SC. Therapeutic Specification of the Last Resort Polymyxins: An Intelligent Approach, Int J Infect. 2019;6(4):e96828. Hasan MJ Rabbani R Bachar SC Therapeutic Specification of the Last Resort Polymyxins: An Intelligent Approach Int J Infect 201964e9682810.5812/iji.96828Search in Google Scholar

26Hasan MJ. Polymyxins Nebulization over Intravenous Injection: Pharmacokinetics and Pharmacodynamics-Based Therapeutic Evaluation. J Pharm Res Int. 2019;25(4):1-10. Hasan MJ Polymyxins Nebulization over Intravenous Injection: Pharmacokinetics and Pharmacodynamics-Based Therapeutic Evaluation J Pharm Res Int 20192541 1010.9734/jpri/2018/v25i430104Search in Google Scholar

27Manchandani P, Zhou J, Ledesma KR, et al. Characterisation of Polymyxin B Biodistribution and Disposition in an Animal Model. Antimicrob Agents Chemother. 2015;60(2):1029-1034. Manchandani P Zhou J Ledesma KR et al Characterisation of Polymyxin B Biodistribution and Disposition in an Animal Model Antimicrob Agents Chemother 20156021029 103410.1128/AAC.02445-15475068926643340Search in Google Scholar

28Landersdorfer CB, Wang J, Wirth V, et al. Pharmacokinetics/ pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models. J Antimicrob Chemother. 2017;73(2):462-468. Landersdorfer CB Wang J Wirth V et al Pharmacokinetics/ pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models J Antimicrob Chemother 2017732462 46810.1093/jac/dkx409589066629149294Search in Google Scholar

29American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med.2005;171(4):388-416. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia Am J Respir Crit Care Med 2005 1714388 41610.1164/rccm.200405-644ST15699079Search in Google Scholar

30Chastre J, Fagon JY. State of the art: ventilator-associated pneumonia. Am J Respir Crit Care Med.2002;165(7):867-903. Chastre J Fagon JY State of the art: ventilator-associated pneumonia Am J Respir Crit Care Med 2002 1657867 90310.1164/ajrccm.165.7.210507811934711Search in Google Scholar

31Hunter JD. Ventilator-associated pneumonia. BMJ.2012;344:e3325. Hunter JD Ventilator-associated pneumonia BMJ 2012 344e332510.1136/bmj.e332522645207Search in Google Scholar

32Kalanuria AA, Ziai W, Mirski M. Ventilator-associated pneumonia in the ICU. Crit Care. 2014;18(2):208. Kalanuria AA Ziai W Mirski M Ventilator-associated pneumonia in the ICU Crit Care 201418220810.1007/978-3-319-03746-2_6Search in Google Scholar

33Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA. 1995;274(8):639-644. Vincent JL Bihari DJ Suter PM et al The prevalence of nosocomial infection in intensive care units in Europe Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 19952748639 64410.1001/jama.1995.03530080055041Search in Google Scholar

34Skrupky LP, McConnell K, Dallas J, Kollef MH. A comparison of ventilator-associated pneumonia rates as identified according to the National Healthcare Safety Network and American College of Chest Physicians Criteria. Crit Care Med.2012;40(1):281-284. Skrupky LP McConnell K Dallas J Kollef MH A comparison of ventilator-associated pneumonia rates as identified according to the National Healthcare Safety Network and American College of Chest Physicians Criteria Crit Care Med 2012 401281 28410.1097/CCM.0b013e31822d791321926609Search in Google Scholar

35Heredia-Rodríguez M, Peláez MT, Fierro I, et al. Impact of ventilator-associated pneumonia on mortality and epidemiological features of patients with secondary peritonitis. Ann Intensive Care. 2016; 6(1):34. Heredia-Rodríguez M Peláez MT Fierro I et al Impact of ventilator-associated pneumonia on mortality and epidemiological features of patients with secondary peritonitis Ann Intensive Care 2016 613410.1186/s13613-016-0137-5483541727090531Search in Google Scholar

36Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).JAMA.2016;315(8):801-810. Singer M Deutschman CS Seymour CW et al The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) JAMA 2016 3158801 81010.1001/jama.2016.0287496857426903338Search in Google Scholar

37Zhao GJ, Li D, Zhao Q, et al. Incidence, risk factors and impact on outcomes of secondary infection in patients with septic shock: an 8-year retrospective study. Sci Rep. 2016; 6:38361. Zhao GJ Li D Zhao Q et al Incidence, risk factors and impact on outcomes of secondary infection in patients with septic shock: an 8-year retrospective study Sci Rep 2016 63836110.1038/srep38361514141527924831Search in Google Scholar

38Christaki E. Host immune response in sepsis due to ventilator-associated pneumonia: How is it different? Crit Care. 2009;13(6):1009. Christaki E Host immune response in sepsis due to ventilator-associated pneumonia: How is it different? Crit Care 2009136100910.1186/cc8174281189720017893Search in Google Scholar

39Ture Z, et al. A Comparison of Nosocomial Infection Density in Intensive Care Units on Relocating to a New Hospital. J Crit Care Med. 2020;6(3):175–80. Ture Z et al A Comparison of Nosocomial Infection Density in Intensive Care Units on Relocating to a New Hospital J Crit Care Med 202063175 8010.2478/jccm-2020-0028743035832864463Search in Google Scholar